TX Houston의 골수형성이상증후군 임상 시험
골수형성이상증후군 관련 연구 44개가 Houston 및 인근(약 30마일 이내) 지역에서 참여자를 모집하고 있습니다. 연구 항목을 열어 참여 자격 및 연구 팀 연락처를 확인하세요.
공식 연구 텍스트(영어)
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
피험자 모집 중1상
- University of Texas MD Anderson Cancer Center, Houston
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
피험자 모집 중2상
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
피험자 모집 중1/2상
- MD Anderson Cancer Center, Houston
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
피험자 모집 중1/2상
- M D Anderson Cancer Center, Houston
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
피험자 모집 중1/2상
- MD Anderson, Houston
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
피험자 모집 중3상
- The University of Texas-MD Anderson Cancer Center - Leukemia Center, Houston
- LUMI Research, Houston
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
피험자 모집 중1상
- M D Anderson Cancer Center, Houston
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
피험자 모집 중2상
- M D Anderson Cancer Center, Houston
A Study of BGB-11417 in Participants With Myeloid Malignancies
피험자 모집 중1/2상
- Md Anderson Cancer Center, Houston
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
피험자 모집 중1/2상
- M D Anderson Cancer Center, Houston
A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)
피험자 모집 중1상
- The University of Texas MD Anderson Cancer Center, Houston
A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
피험자 모집 중2상건강한 지원자 환영
- MD Anderson Cancer Center, Houston
ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
피험자 모집 중1/2상
- M D Anderson Cancer Center, Houston
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
피험자 모집 중3상
- MD Anderson Cancer Centre, Houston
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
피험자 모집 중2상
- M D Anderson Cancer Center, Houston
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
피험자 모집 중1/2상
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- UT MD Anderson Cancer Center, Houston
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
피험자 모집 중3상
- U.T. MD Anderson Cancer Center, Division of Cancer Medicine, Houston
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
피험자 모집 중2상
- Univ of Texas MD Anderson Cancer Center, Division of Cancer Medicine, Houston
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
피험자 모집 중2/3상건강한 지원자 환영
- M D Anderson Cancer Center, Houston
Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
피험자 모집 중1/2상
- MD Anderson Cancer Center, Houston
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
피험자 모집 중1/2상
- M D Anderson Cancer Center, Houston
Personalized NK Cell Therapy in CBT
피험자 모집 중2상
- M D Anderson Cancer Center, Houston
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
피험자 모집 중1/2상
- Research Site, Houston
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
피험자 모집 중2상
- University of Texas MD Anderson Cancer Center, Houston
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
피험자 모집 중2상
- M D Anderson Cancer Center, Houston
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
피험자 모집 중1상
- MD Anderson Cancer Center, Houston
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
피험자 모집 중1상
- MD Anderson Cancer Center, Houston
A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts
피험자 모집 중2상
- M D Anderson Cancer Center, Houston
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
피험자 모집 중2상
- GSK Investigational Site, Houston
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment
피험자 모집 중1상
- MD Anderson, Houston
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment
피험자 모집 중1상
- MD Anderson, Houston
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
피험자 모집 중2상
- M D Anderson Cancer Center, Houston
A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
피험자 모집 중2상
- M D Anderson Cancer Center, Houston
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
피험자 모집 중2/3상
- MD Anderson Cancer Center, Houston
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
피험자 모집 중1/2상
- The University of Texas MD Anderson Cancer Center, Houston
Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
피험자 모집 중1상
- University of Texas MD Anderson Cancer Center, Houston
Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
피험자 모집 중1상
- MD Anderson Cancer Center, Houston
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
피험자 모집 중1/2상
- MDACC, Houston
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
피험자 모집 중1상
- MD Anderson, Houston
Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML
피험자 모집 중1상건강한 지원자 환영
- M.D. Anderson Cancer Center, Department of Leukemia, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
피험자 모집 중관찰 연구
- Massive Bio SYNERGY-AI site, Houston
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
피험자 모집 중1상
- The University of Texas M.D. Anderson Cancer Center, Houston
Study of REM-422 in Patients With AML or Higher Risk MDS
피험자 모집 중1상
- MD Anderson Cancer Center, Houston
A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
피험자 모집 중1상
- The University of Texas MD Anderson Cancer Center, Houston
다른 도시의 골수형성이상증후군 시험
- Baldwin Park, CA연구 26개
- Seattle, WA연구 21개
- New York City, NY연구 21개
- Boston, MA연구 20개
- Washington, DC연구 20개
- Tampa, FL연구 19개
- Miami, FL연구 17개
- Chicago, IL연구 14개
- Columbus, OH연구 14개
- St. Louis, MO연구 14개
- Durham, NC연구 14개
- Atlanta, GA연구 13개
Houston의 다른 연구
- 비소세포폐암연구 145개
- 유방암연구 126개
- 암 (전체)연구 122개
- 전이성 암연구 104개
- 대장직장암연구 103개
- 난소암연구 90개
- 급성 골수성 백혈병연구 86개
- 폐암연구 78개
- 전립선암연구 76개
- 자궁내막암연구 69개
- 췌장암연구 62개
- 흑색종연구 59개
ClinicalTrials.gov 출처, 2026. 10. 1. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.